Literature DB >> 23563022

Effect of human interleukin-10 on the expression of nitric oxide synthases in the MPTP-based model of Parkinson's disease.

Joanna Schwenkgrub1, Ilona Joniec-Maciejak, Anna Sznejder-Pachołek, Adriana Wawer, Agnieszka Ciesielska, Krzysztof Bankiewicz, Anna Członkowska, Andrzej Członkowski.   

Abstract

BACKGROUND: Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder. The degeneration of the nigro-striatal pathway has been linked with the inflammatory process accompanied by the robust up-regulation of the nitric oxide synthase (NOS) and production of the neurotoxic level of nitric oxide (NO). One of the therapeutic strategies of PD is based on the reduction of the detrimental neuroinflammatory markers in the lesioned nigro-striatal pathway. In this study we have investigated the neuroprotective effect of the cerebral infusion of recombinant adeno-associated viral vector, expressing the gene for human interleukin-10 (AAV2-hIL-10) in a mouse model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). It is known that IL-10 is a potent anti-inflammatory cytokine that limits the inducible nitric oxide synthase (iNOS) gene expression.
METHODS: The striatal iNOS, neuronal nitric oxide synthase (nNOS) and tyrosine hydroxylase (TH) protein expression was evaluated by immunoblot analysis.
RESULTS: The intracerebral injection of the AAV2-hIL-10, before the lesion, induced the upregulation of the striatal TH protein, depleted by MPTP intoxication. This AAV2-hIL-10-induced increase of TH level was associated with the suppression of iNOS protein expression in the lesioned striatum.
CONCLUSION: The results revealed protective properties of AAV2-hIL-10.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23563022     DOI: 10.1016/s1734-1140(13)70962-9

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  14 in total

Review 1.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

Review 2.  M1 and M2 immune activation in Parkinson's Disease: Foe and ally?

Authors:  M S Moehle; A B West
Journal:  Neuroscience       Date:  2014-11-25       Impact factor: 3.590

Review 3.  Therapeutic Strategies for Immune Transformation in Parkinson's Disease.

Authors:  Maamoon Saleh; Milica Markovic; Katherine E Olson; Howard E Gendelman; R Lee Mosley
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 4.  The Contribution of Microglia to Neuroinflammation in Parkinson's Disease.

Authors:  Katja Badanjak; Sonja Fixemer; Semra Smajić; Alexander Skupin; Anne Grünewald
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

5.  The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.

Authors:  Joanna Schwenkgrub; Malgorzata Zaremba; Ilona Joniec-Maciejak; Agnieszka Cudna; Dagmara Mirowska-Guzel; Iwona Kurkowska-Jastrzębska
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

Review 6.  Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.

Authors:  Sudhakar R Subramaniam; Howard J Federoff
Journal:  Front Aging Neurosci       Date:  2017-06-08       Impact factor: 5.750

Review 7.  Interglial Crosstalk in Obesity-Induced Hypothalamic Inflammation.

Authors:  Md Habibur Rahman; Min-Seon Kim; In-Kyu Lee; Rina Yu; Kyoungho Suk
Journal:  Front Neurosci       Date:  2018-12-13       Impact factor: 4.677

Review 8.  Pharmacological Targeting of Microglial Activation: New Therapeutic Approach.

Authors:  Cai-Yun Liu; Xu Wang; Chang Liu; Hong-Liang Zhang
Journal:  Front Cell Neurosci       Date:  2019-11-19       Impact factor: 5.505

9.  Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice.

Authors:  Tcs Costa; E Fernandez-Villalba; V Izura; A M Lucas-Ochoa; N J Menezes-Filho; R C Santana; M D de Oliveira; F M Araújo; C Estrada; Vda Silva; S L Costa; M T Herrero
Journal:  J Neuroimmune Pharmacol       Date:  2020-06-21       Impact factor: 4.147

10.  Curcumin-Activated Mesenchymal Stem Cells Derived from Human Umbilical Cord and Their Effects on MPTP-Mouse Model of Parkinson's Disease: A New Biological Therapy for Parkinson's Disease.

Authors:  Yun-Liang Wang; Xin-Shan Liu; Shan-Shan Wang; Peng Xue; Zhi-Lei Zeng; Xiao-Peng Yang; Si-Miao Zhang; Wei Zheng; Linlin Hua; Jin-Feng Li; Hai-Tao Wang; Shang Guo
Journal:  Stem Cells Int       Date:  2020-02-17       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.